A Safety Study of BBI-4000 Gel in Patients With Axillary Hyperhidrosis
Status:
Completed
Trial end date:
2020-01-27
Target enrollment:
Participant gender:
Summary
Hyperhidrosis is a disorder of abnormal excessive sweating. Primary hyperhidrosis (armpits,
hands, and feet) affects approximately 4.8% of the US population and is believed to be caused
by an overactive cholinergic response of the sweat glands. Current therapies have limited
effectiveness, significant side effects, and can be invasive and costly. Sofpironium bromide
(BBI-4000) is a novel soft-drug in development for the topical treatment of hyperhidrosis.
This Phase 3 study will assess the long-term safety, tolerability, and efficacy of
sofpironium bromide gel applied topically to subjects with axillary hyperhidrosis.